Oseltamivir enhances 5-FU sensitivity in esophageal squamous carcinoma with high SPNS1
Biomed Pharmacother. 2024 Mar 8;173:116367. doi: 10.1016/j.biopha.2024.116367. Online ahead of print.ABSTRACTSphingolipid transporter 1 (SPNS1) is a significant differentially expressed gene (DEGs) in esophageal squamous cell carcinoma (ESCC). According to 3 pairs clinic cohorts, transcriptomic (155 pairs of ESCC samples and GSE53624, and proteomic data from PXD021701 including 124 ESCC samples) we found that SPNS1 was significantly higher in ESCC tissues compared to adjacent normal esophagus tissues. ESCC patients with high SPNS1 had a significantly poorer clinical prognosis than those with low SPNS1. Knockdown of SPNS1 s...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 9, 2024 Category: Drugs & Pharmacology Authors: Xin Yang Ye Jiao Yingying Zhang Meng Sun Yingzhen Gao Yan Zhou Heng Xiao Jing Ren Zhinan Zhou Yuanfang Zhai Bin Song Ling Zhang Pengzhou Kong Source Type: research
Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022-2023 season
Antiviral Res. 2024 Feb 29:105853. doi: 10.1016/j.antiviral.2024.105853. Online ahead of print.ABSTRACTWhile clinical trials have illuminated both the virological and clinical efficacy of baloxavir for influenza and post-treatment viral resistance, these aspects warrant further study in real-world settings. In response, we executed a prospective, observational study of the Japanese 2022-2023 influenza season. A cohort of 73 A(H3N2)-diagnosed outpatients-36 treated with baloxavir, 20 with oseltamivir, and 17 with other neuraminidase inhibitors (NAIs)-were analyzed. Viral samples were collected before and after administering...
Source: Antiviral Research - March 2, 2024 Category: Virology Authors: Takeyuki Goto Naoki Kawai Takuma Bando Yoshio Takasaki Shizuo Shindo Naoki Tani Yong Chong Hideyuki Ikematsu Source Type: research
Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022-2023 season
Antiviral Res. 2024 Feb 29:105853. doi: 10.1016/j.antiviral.2024.105853. Online ahead of print.ABSTRACTWhile clinical trials have illuminated both the virological and clinical efficacy of baloxavir for influenza and post-treatment viral resistance, these aspects warrant further study in real-world settings. In response, we executed a prospective, observational study of the Japanese 2022-2023 influenza season. A cohort of 73 A(H3N2)-diagnosed outpatients-36 treated with baloxavir, 20 with oseltamivir, and 17 with other neuraminidase inhibitors (NAIs)-were analyzed. Viral samples were collected before and after administering...
Source: Antiviral Research - March 2, 2024 Category: Virology Authors: Takeyuki Goto Naoki Kawai Takuma Bando Yoshio Takasaki Shizuo Shindo Naoki Tani Yong Chong Hideyuki Ikematsu Source Type: research
Viruses, Vol. 16, Pages 388: Impact of the H274Y Substitution on N1, N4, N5, and N8 Neuraminidase Enzymatic Properties and Expression in Reverse Genetic Influenza A Viruses
In conclusion, the H274Y-NA substitution of different group-1-NAs systematically reduced their affinity for MUNANA substrate without a significant impact on NA Vm. The impact of the H274Y-NA substitution on viral NA expression was different according to the studied NA. (Source: Viruses)
Source: Viruses - March 1, 2024 Category: Virology Authors: Alexandre Gaymard Caroline Picard Guilhem Vazzoler Pascale Massin Emilie Frobert Murielle Sabatier Mendy Barthelemy Martine Valette Mich èle Ottmann Jean-S ébastien Casalegno Bruno Lina Vanessa Escuret Tags: Communication Source Type: research
Impact of oseltamivir on the risk of cancer
ConclusionThese findings first suggest the beneficial effects and therapeutic potential of OP use for certain cancers, especially liver cancer. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - February 26, 2024 Category: Cancer & Oncology Source Type: research
An extensive database analysis demonstrates significant increase in platelet quantity in unselected hospitalized patients following treatment with oseltamivir
Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.283731. Online ahead of print.ABSTRACTNot available.PMID:38385256 | DOI:10.3324/haematol.2023.283731 (Source: Haematologica)
Source: Haematologica - February 22, 2024 Category: Hematology Authors: Chandrasekar Muthiah Qinghua Lian Samantha Benz Aniko Szabo Karin Hoffmeister Juliana Perez Botero Laura C Michaelis Source Type: research
An extensive database analysis demonstrates significant increase in platelet quantity in unselected hospitalized patients following treatment with oseltamivir
Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.283731. Online ahead of print.ABSTRACTNot available.PMID:38385256 | DOI:10.3324/haematol.2023.283731 (Source: Haematologica)
Source: Haematologica - February 22, 2024 Category: Hematology Authors: Chandrasekar Muthiah Qinghua Lian Samantha Benz Aniko Szabo Karin Hoffmeister Juliana Perez Botero Laura C Michaelis Source Type: research
An extensive database analysis demonstrates significant increase in platelet quantity in unselected hospitalized patients following treatment with oseltamivir
Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.283731. Online ahead of print.ABSTRACTNot available.PMID:38385256 | DOI:10.3324/haematol.2023.283731 (Source: Haematologica)
Source: Haematologica - February 22, 2024 Category: Hematology Authors: Chandrasekar Muthiah Qinghua Lian Samantha Benz Aniko Szabo Karin Hoffmeister Juliana Perez Botero Laura C Michaelis Source Type: research
An extensive database analysis demonstrates significant increase in platelet quantity in unselected hospitalized patients following treatment with oseltamivir
Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.283731. Online ahead of print.ABSTRACTNot available.PMID:38385256 | DOI:10.3324/haematol.2023.283731 (Source: Haematologica)
Source: Haematologica - February 22, 2024 Category: Hematology Authors: Chandrasekar Muthiah Qinghua Lian Samantha Benz Aniko Szabo Karin Hoffmeister Juliana Perez Botero Laura C Michaelis Source Type: research
An extensive database analysis demonstrates significant increase in platelet quantity in unselected hospitalized patients following treatment with oseltamivir
Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.283731. Online ahead of print.ABSTRACTNot available.PMID:38385256 | DOI:10.3324/haematol.2023.283731 (Source: Haematologica)
Source: Haematologica - February 22, 2024 Category: Hematology Authors: Chandrasekar Muthiah Qinghua Lian Samantha Benz Aniko Szabo Karin Hoffmeister Juliana Perez Botero Laura C Michaelis Source Type: research
An extensive database analysis demonstrates significant increase in platelet quantity in unselected hospitalized patients following treatment with oseltamivir
Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.283731. Online ahead of print.ABSTRACTNot available.PMID:38385256 | DOI:10.3324/haematol.2023.283731 (Source: Haematologica)
Source: Haematologica - February 22, 2024 Category: Hematology Authors: Chandrasekar Muthiah Qinghua Lian Samantha Benz Aniko Szabo Karin Hoffmeister Juliana Perez Botero Laura C Michaelis Source Type: research
An extensive database analysis demonstrates significant increase in platelet quantity in unselected hospitalized patients following treatment with oseltamivir
Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.283731. Online ahead of print.ABSTRACTNot available.PMID:38385256 | DOI:10.3324/haematol.2023.283731 (Source: Haematologica)
Source: Haematologica - February 22, 2024 Category: Hematology Authors: Chandrasekar Muthiah Qinghua Lian Samantha Benz Aniko Szabo Karin Hoffmeister Juliana Perez Botero Laura C Michaelis Source Type: research
Progress of Influenza Viruses and Inhibitors
Curr Med Chem. 2024 Feb 15. doi: 10.2174/0109298673268314231204061224. Online ahead of print.ABSTRACTInfluenza is an acute respiratory disease caused by influenza viruses. It has the characteristics of fast transmission and strong infectivity, and it does great harm to human health and survival. It is estimated that the seasonal influenza epidemics every year will cause about one billion cases of infections and hundreds of thousands of deaths worldwide, while influenza A virus is the leading cause of infection and death. Currently, the main drugs used in clinics to treat influenza viruses are neuraminidase inhibitors, and ...
Source: Current Medicinal Chemistry - February 16, 2024 Category: Chemistry Authors: Yuchen Xiao Jianping Yong Shaoji Lu Canzhong Lu Ruiwen Huang Source Type: research
Progress of Influenza Viruses and Inhibitors
Curr Med Chem. 2024 Feb 15. doi: 10.2174/0109298673268314231204061224. Online ahead of print.ABSTRACTInfluenza is an acute respiratory disease caused by influenza viruses. It has the characteristics of fast transmission and strong infectivity, and it does great harm to human health and survival. It is estimated that the seasonal influenza epidemics every year will cause about one billion cases of infections and hundreds of thousands of deaths worldwide, while influenza A virus is the leading cause of infection and death. Currently, the main drugs used in clinics to treat influenza viruses are neuraminidase inhibitors, and ...
Source: Current Medicinal Chemistry - February 16, 2024 Category: Chemistry Authors: Yuchen Xiao Jianping Yong Shaoji Lu Canzhong Lu Ruiwen Huang Source Type: research
Discovery of cyperenoic acid as a potent and novel entry inhibitor of influenza A virus
Antiviral Res. 2024 Feb 11:105822. doi: 10.1016/j.antiviral.2024.105822. Online ahead of print.ABSTRACTInfluenza therapeutics with new targets and modes of action are urgently needed due to the frequent emergence of mutants resistant to currently available anti-influenza drugs. Here we report the in vitro and in vivo anti-influenza A virus activities of cyperenoic acid, a natural compound, which was isolated from a Chinese medicine Croton crassifolius Geise. Cyperenoic acid could potently suppress H1N1, H3N2 and H9N2 virus replication with IC50 values ranging from 0.12 to 15.13 μM, and showed a low cytotoxicity against MD...
Source: Antiviral Research - February 13, 2024 Category: Virology Authors: Xiaoli Zhang Yiping Xia Peibo Li Zhongnan Wu Ruilin Li Jialiao Cai Yubo Zhang Guocai Wang Yaolan Li Wei Tang Weiwei Su Source Type: research
